Erika Rebello
Adult Health · Fall River, MANPI 1710521315
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 276 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 21.7% — the pattern of someone who eats at a lot of different presentations. Among adult health clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 276 payments — averaging $18.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- AbbVie$671
- Pfizer$553
- Novo Nordisk$372
- Merck$295
- Bayer$284
- plus $2K from 27 others
What the payments were for
- Food & beverage$5,147100%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 39 | $1,122 |
| AbbVie | 59 | $671 |
| Pfizer | 41 | $553 |
| Novo Nordisk | 18 | $372 |
| Merck | 13 | $295 |
| Bayer | 18 | $284 |
| Novartis | 15 | $260 |
| Vanda Pharmaceuticals Inc. | 9 | $227 |
| Johnson & Johnson | 7 | $214 |
| Ardelyx, Inc. | 8 | $160 |
| Abbott | 1 | $125 |
| Boehringer Ingelheim | 5 | $124 |
| GSK | 7 | $115 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $83 |
| E.r. Squibb & Sons, L.L.C. | 4 | $79 |
| Lilly USA, LLC | 3 | $63 |
| Otsuka America Pharmaceutical, Inc. | 3 | $53 |
| Amgen | 2 | $47 |
| Neurocrine Biosciences, Inc. | 1 | $33 |
| Grifols USA, LLC | 2 | $31 |
| Philips North America LLC | 1 | $27 |
| Mylan Specialty L.p. | 2 | $26 |
| Nestle Healthcare Nutrition Inc. | 1 | $23 |
| Corcept Therapeutics | 1 | $23 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $23 |
| Phathom Pharmaceuticals, Inc. | 2 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Exact Sciences | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Viatris Specialty LLC | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Lundbeck LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,168 in reported general payments places this provider in the 95th percentile of 671 adult health providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HetliozTasimelteon | 11 | $246,185 |
| OzempicSemaglutide | 91 | $107,315 |
| EliquisApixaban | 50 | $51,212 |
| IbsrelaTenapanor Hcl | 20 | $49,926 |
| RybelsusSemaglutide | 22 | $32,741 |
| TrulicityDulaglutide | 31 | $30,068 |
| VraylarCariprazine Hcl | 17 | $29,880 |
| LinzessLinaclotide | 23 | $28,151 |
| MounjaroTirzepatide | 26 | $28,070 |
| JardianceEmpagliflozin | 18 | $22,883 |
| FarxigaDapagliflozin Propanediol | 20 | $19,695 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $19,464 |
| GlyxambiEmpagliflozin/Linagliptin | 18 | $16,912 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $7,484 |
| Dexlansoprazole DrDexlansoprazole | 13 | $7,027 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Vanda Pharmaceuticals Inc.Hetlioz | $227 | $246,18511 claims |
| Novo NordiskOzempic, Rybelsus | $372 | $140,056113 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $63 | $58,13957 claims |
| AbbVieVraylar, Linzess | $671 | $58,03140 claims |
| PfizerEliquis | $553 | $51,21250 claims |
| Ardelyx, Inc.Ibsrela | $160 | $49,92620 claims |
| Boehringer IngelheimJardiance, Glyxambi | $124 | $39,79636 claims |
| AstraZenecaFarxiga, Symbicort | $1,122 | $23,70437 claims |
| GSKTrelegy Ellipta | $115 | $19,46419 claims |
| BayerKerendia | $284 | $7,01111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 671 adult health providers in Massachusetts.
Other adult health in Fall River
- Tiffini ReedyFall River$58K
- Ann-Marie McCabeFall River$6K
- Rachel ResendesFall River$5K
- Kevin BlanchardFall River$4K
- Kristen CarrollFall River$4K
- Kathleen ElliottFall River$4K
- Susan NavarroFall River$3K
- Jennifer GillisFall River$3K
- Krista TuckerBoston$157K
- Kathleen Dietz LovettHyannis$123K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.